



ANNOUNCEMENT NO. 205

20 May 2021

Revenue and EBITDA guidance raised

ChemoMetec has continued its positive development into the latter part of the financial year 2020/21, where sales and order intake in May in the North American market in particular develop significantly better than expected, supposedly due to the reopening of laboratories and replenishment of inventories.

As a result of the higher revenue and the continued low sales-related expenses, especially due to the COVID-19 restrictions, ChemoMetec is raising its guidance for both revenue and EBITDA for the 2020/21 financial year.

ChemoMetec now expects revenue in the DKK 275-278 million range, up from DKK 263-268 million, and EBITDA in the DKK 130-133 million range, up from DKK 120-125 million.

ChemoMetec expects to release its 2020/21 Annual Report on Thursday, 16 September 2021.

For further information, please contact

Steen Søndergaard, CEO, ChemoMetec A/S

Tel.: (+45) 4813 1020

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com.